JAMP PRASUGREL TABLET Կանադա - անգլերեն - Health Canada

jamp prasugrel tablet

jamp pharma corporation - prasugrel (prasugrel hydrochloride) - tablet - 10mg - prasugrel (prasugrel hydrochloride) 10mg - platelet aggregation inhibitors

Prasugrel Rowex 5 mg Film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prasugrel rowex 5 mg film-coated tablets

rowex ltd - prasugrel besilate - film-coated tablet - 5 milligram(s) - platelet aggregation inhibitors excl. heparin; prasugrel

Prasugrel Rowex 10 mg Film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prasugrel rowex 10 mg film-coated tablets

rowex ltd - prasugrel - film-coated tablet - 10 milligram(s) - platelet aggregation inhibitors excl. heparin; prasugrel

Prasugrel Krka 5 mg Film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prasugrel krka 5 mg film-coated tablets

krka, d.d., novo mesto - prasugrel - film-coated tablet - 5 milligram(s) - platelet aggregation inhibitors excl. heparin; prasugrel

Prasugrel Krka 10 mg Film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prasugrel krka 10 mg film-coated tablets

krka, d.d., novo mesto - prasugrel - film-coated tablet - 10 milligram(s) - platelet aggregation inhibitors excl. heparin; prasugrel

Prasugrel Accord 10 mg film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prasugrel accord 10 mg film-coated tablets

accord healthcare ireland ltd. - prasugrel - film-coated tablet - 10 milligram(s) - platelet aggregation inhibitors excl. heparin; prasugrel

Prasugrel Accord 5 mg film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prasugrel accord 5 mg film-coated tablets

accord healthcare ireland ltd. - prasugrel - film-coated tablet - 5 milligram(s) - platelet aggregation inhibitors excl. heparin; prasugrel

PRASUGREL TEVA 10 MG Իսրայել - անգլերեն - Ministry of Health

prasugrel teva 10 mg

abic marketing ltd, israel - prasugrel as hydrobromide - film coated tablets - prasugrel as hydrobromide 10 mg - prasugrel - prasugrel teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci). the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 or weight below 60 kg.

PRASUGREL TEVA 5 MG Իսրայել - անգլերեն - Ministry of Health

prasugrel teva 5 mg

abic marketing ltd, israel - prasugrel as hydrobromide - film coated tablets - prasugrel as hydrobromide 5 mg - prasugrel - prasugrel teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci). the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 or weight below 60 kg.

PRASUGREL AJS prasugrel 10 mg film-coated tablets blister pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

prasugrel ajs prasugrel 10 mg film-coated tablets blister pack

southern cross pharma pty ltd - prasugrel, quantity: 10 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; crospovidone; microcrystalline cellulose; sucrose stearate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - prasugrel, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).